NCT01592110View on ClinicalTrials.gov

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Schizophrenia
Interventions
DRUG

risperidone-SABER

25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL

OTHER

ZX003:risperidone-SABER and the DosePro System

50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System

DRUG

risperidone-SABER

50 mg of risperidone-SABER administered as a SC injection of 0.5 mL

DRUG

Risperidone-SABER

100 mg of risperidone-SABER administered as a SC injection of 1.0 mL

Trial Locations (1)

91206

Glendale Adventist Medical Center, Glendale

All Listed Sponsors
lead

Zogenix, Inc.

INDUSTRY

NCT01592110 - A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter